Navigation Links
Reliance Pharmaceuticals: Biosimilars Company Analysis
Date:9/20/2012

NEW YORK, Sept. 20, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

Reliance Pharmaceuticals: Biosimilars Company Analysis

http://www.reportlinker.com/p0968557/Reliance-Pharmaceuticals-Biosimilars-Company-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical

 

This analysis evaluates the company's strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company's biosimilars portfolio, including analysis of key product profiles, examining key drivers and resistors to development, market sizing, specifics of development such as clinical trials (where available) for each key biosimilar molecule in development.Strategic insight into the key strategies that have shaped the company's progress and/or will define its outlook going forward.Provides an indication of how biosimilars fit into the wider company context, and a history of deals & alliances.Reliance Life Sciences has a primary focus on biopharmaceuticals and pharmaceuticals, but also a presence in the wider areas of clinical research services, regenerative medicine, molecular medicine, and biofuels. The overall sales of Reliance Life Sciences totaled $104.7m in FY2011, with approximately 70% coming from biopharmaceutical products.Assess Reliance's portfolio of 7 marketed biosimilars and 20 pipeline products, which includes 3 monoclonal antibody productsSee how the 2007 acquisition of GeneMedix will help diversify Reliance's geographical focus

 

 

 

ABOUT THIS REPORT•Chapter structure - Strategic insight

- Product analysis

- Corporate structure

 

•Data sourcing

•PharmaVitae Explorer database

 

EXECUTIVE SUMMARY•Reliance Life Sciences biosimilars overview

•Reliance Life Sciences biosimilars infrastructure

 

STRATEGIC INSIGHT•Reliance Life Sciences made the strategic acquisition of GeneMedix to penetrate the European markets

•Reliance is focusing on the oncology therapy area and developing a portfolio of MAb biosimilars - Oncology focus

 

•Reliance Life Sciences biosimilars SWOT analysis - Strengths

- Weaknesses

- Opportunities

- Threats

 

 

KEY PRODUCTS•Reliance Life Sciences biosimilars portfolio

•ReliPoietin (epoetin alfa) - Overview

- Erythropoietin market size

- Key competitors

 

•ReliGrast (filgrastim)Reliance Life Sciences launched biosimilar granulocyte colony-stimulating factor (GCSF) ReliGrast in 2008. It is currently marketed in India and other semi-regulated markets. - Filgrastim and pegfilgrastim market size

- Key competitors

 

•ReliFeron (interferon alfa-2b) - Overview

- Interferon alfa market size

- Key competitors

 

•FostiRel (follitropin beta) - Market overview

- Key competitors

 

•ReliBeta (interferon beta-1a) - Overview

- Interferon beta market size

- Key competitors

- Reliance Life Sciences' other marketed products and biosimilar development

 

 

CORPORATE STRUCTURE•Background

•Key corporate developments

•Company structure - Biopharmaceuticals

- Novel therapeutics

- Pharmaceuticals

- Clinical research services

- Regenerative medicine

- Molecular medicine

- Plant biotechnology

- Industrial biotechnology

 

•Deals and alliances

•Recent developments

 

APPENDIX•References - Datamonitor reports

 

•Exchange rates

 

 

TABLES

•Table: Reliance Life Sciences biosimilars development and marketing capabilities

•Table: Forecast global sales of infliximab, rituximab, and abciximab ($m), 2011–16

•Table: Reliance Life Sciences – life sciences initiatives

•Table: Reliance Life Sciences – biosimilar/copy-biologic portfolio

•Table: Forecast epoetin sales in the seven major markets ($m), 2011–16

•Table: Reliance Life Sciences – pipeline and marketed biosimilar/copy-biologic epoetin and darbepoetin drugs

•Table: Forecast filgrastim and pegfilgrastim sales in the seven major markets ($m), 2011–16

•Table: Reliance Life Sciences – pipeline and marketed biosimilar/copy-biologic filgrastim and pegfilgrastim drugs

•Table: Forecast interferon alfa and peginterferon alfa sales in the seven major markets ($m), 2011–16

•Table: Reliance Life Sciences – pipeline and marketed biosimilar/copy-biologic interferon alfa

•Table: Forecast follitropin alfa and beta sales in the seven major markets ($m), 2011–16

•Table: Biosimilar/copy-biologic follitropin drugs, 2012

•Table: Forecast interferon beta sales in the seven major markets ($m), 2011–16

•Table: Reliance Life Sciences – pipeline and marketed biosimilar/copy-biologic interferon beta drugs

•Table: Reliance Life Sciences – monoclonal antibodies under development

•Table: Reliance Life Sciences/GeneMedix deal activity and biosimilar deals, 2000?12

•Table: Exchange rates, 2012

 

 

FIGURES

•Figure: The PharmaVitae Explorer

•Figure: Reliance Life Sciences biosimilars overview

•Figure: Mutual benefits through Reliance Life Sciences' acquisition of GeneMedix

•Figure: Reliance Life Sciences – biosimilar and pharmaceutical products and therapy area

•Figure: Reliance Life Sciences SWOT analysis

•Figure: Proportion of government and private health expenditure versus personal disposable income, in India and other major markets, 2009

•Figure: Reliance Life Sciences – revenues, FY2010–12

•Figure: Reliance Life Sciences – revenues, FY2010?12

•Figure: Reliance Life Sciences – company structure

 

 

 

Companies Mentioned

Antares Pharma, Inc., Asian Development Bank, CJ Corporation, Hutchison 3G UK Limited, Janssen Pharmaceuticals, Inc., Merck KGaA, Reliance Industries Limited, Schindler Holding Ltd.

 

 

 

To order this report:

Biopharmaceutical Industry: Reliance Pharmaceuticals: Biosimilars Company Analysis

 

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

 


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmaceuticals: Global Industry Almanac, MarketLine
2. OTC Pharmaceuticals: Global Industry Almanac, MarketLine
3. Biosimilars in Emerging Economies - Advanced Recombinant Technology Platforms and Low Cost Manufacturing Put India and China at a Strategic Advantage in Biosimilar Production
4. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
5. Selexys Pharmaceuticals Completes $23M Equity Financing and Signs Agreement With Global Pharmaceutical Company
6. Mersana Therapeutics Named a "Fierce 15" Biotech Company for 2012
7. Donor Alliance Named Colorados Top Healthcare Company
8. Aoxing Pharmaceutical Company, Inc. Declines To Comment On Market Activity
9. Perrigo Company To Acquire Assets Of Sergeants Pet Care Products, Inc., For $285 Million
10. Elbit Imaging Ltd. Announces Standard & Poors Maalot Changes Rating of Companys Notes
11. Perrigo Company To Present At The Morgan Stanley Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... N.Y. , Dec. 6, 2016  Licenders is bringing their ... This new location in Park Slope at 203 13 th ... Brooklyn clientele. "Our goal is to ... treatment plans are designed to get children right back to class ... are 100% all natural and safe for the whole family," Licenders ...
(Date:12/6/2016)... Dec. 6, 2016  Alopexx Oncology, LLC announced data ... antibody fusion protein (immunocytokine) composed of interleukin-2 and a ... target on B cells as Rituxan and maintains the ... is also involved in tumor targeting, engagement of the ... The results of the study (abstract #95954) were presented ...
(Date:12/6/2016)... 2016  "Blood Tests replace Surgical Biopsies. Single ... The Diagnostic, Monitoring and Screening Test opportunities are ... occurring using in vitro blood testing to identify ... backing, has announced a single blood test to ... than the market. New technology that definitively identifies ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... ... Mount Sinai Health System today announced the creation of the Medical Modeling ... order 3D models for their cases. Virtual reality, simulation, and 3D printing services ... resource will be the first of its kind catering to the unique patient-specific modeling ...
(Date:12/6/2016)... ... December 06, 2016 , ... The Touchpoint Solution’s new neuroscience wearable, ... Almost 200 backers pledged more than $25,000 on Kickstarter to bring ... Dr. Amy Serin, an Arizona Neuropsychologist and inventor, says she feels like she stumbled ...
(Date:12/6/2016)... ... 06, 2016 , ... After 30 years with The Hearing ... announced her retirement from HASA at the end of 2016. ... individuals and families with hearing and speech services. She has overseen the establishment ...
(Date:12/6/2016)... ... ... It can be argued that people these days spend as much time searching ... their human friends and family. As pets have assumed a bigger role in ... pet products has also increased. , For this reason, America’s Pet Health ...
(Date:12/6/2016)... Atlanta, GA (PRWEB) , ... December 06, 2016 ... ... innovation and the impact of new federal healthcare regulations at the 7th annual ... Galleria Centre, Atlanta. , Andy Slavitt, acting administrator for the Centers for Medicare ...
Breaking Medicine News(10 mins):